chronic myelomonocytic leukemia (Cancer)
Information
- Disease name
- chronic myelomonocytic leukemia
- Disease ID
- DOID:0080188
- Description
- "A chronic leukemia characterized by monocytosis, increased monocytes in the bone marrow, variable degrees of dysplasia, but an absence of immature granulocytes in the blood." [url:https\://en.wikipedia.org/wiki/Chronic_myelomonocytic_leukemia, url:https\://www.ncbi.nlm.nih.gov/pubmed/30367269, url:https\://www.ncbi.nlm.nih.gov/pubmed/31093889]
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT04761770 | Active, not recruiting | Phase 2 | Study of a Geriatric Assessment to Plan a Treatment Approach for Older People With Various Blood Disorders | February 15, 2021 | February 2025 |
| NCT05024994 | Active, not recruiting | Phase 2 | A Study of E7820 in People With Bone Marrow (Myeloid) Cancers | August 13, 2021 | August 2024 |
| NCT04609826 | Active, not recruiting | Phase 1 | A Study of JNJ-74856665 in Participants With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) | November 26, 2020 | July 31, 2024 |
| NCT04522895 | Active, not recruiting | Phase 2 | IDH2-Post-Allo-Trial for Patients With IDH2-mut Myeloid Neoplasms After Allo-SCT | August 27, 2020 | August 30, 2024 |
| NCT00843882 | Active, not recruiting | Phase 3 | Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia | January 29, 2009 | September 21, 2024 |
| NCT02684162 | Active, not recruiting | Phase 2 | Guadecitabine and Donor Lymphocyte Infusion in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Relapsing After Allogeneic Stem Cell Transplant | June 22, 2016 | December 31, 2024 |
| NCT03722407 | Active, not recruiting | Phase 2 | Ruxolitinib for the Treatment of Chronic Myelomonocytic Leukemia (CMML): A Phase 2 Expansion | August 28, 2019 | July 1, 2024 |
| NCT03289910 | Active, not recruiting | Phase 2 | Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia | September 24, 2018 | December 21, 2024 |
| NCT01139970 | Active, not recruiting | Phase 1 | Veliparib and Temozolomide in Treating Patients With Acute Leukemia | May 21, 2010 | February 22, 2025 |
| NCT00392353 | Active, not recruiting | Phase 1/Phase 2 | Vorinostat and Azacitidine in Treating Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia | November 22, 2006 | September 30, 2024 |
| NCT02935361 | Active, not recruiting | Phase 1/Phase 2 | Guadecitabine and Atezolizumab in Treating Patients With Advanced Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia That Is Refractory or Relapsed | November 2, 2016 | November 30, 2025 |
| NCT01522976 | Active, not recruiting | Phase 2 | Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia | March 1, 2012 | March 7, 2025 |
| NCT04473911 | Active, not recruiting | Phase 1 | Haplo Peripheral Blood Sct In GVHD Prevention | August 14, 2020 | October 2024 |
| NCT02566304 | Active, not recruiting | Phase 2 | Reduced Intensity Chemotherapy and Radiation Therapy Before Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies | November 13, 2015 | February 13, 2024 |
| NCT03404193 | Active, not recruiting | Phase 2 | Venetoclax and Decitabine in Treating Participants With Relapsed/Refractory Acute Myeloid Leukemia or Relapsed High-Risk Myelodysplastic Syndrome | January 18, 2018 | December 31, 2024 |
| NCT00588991 | Active, not recruiting | Phase 1 | Veliparib and Topotecan With or Without Carboplatin in Treating Patients With Relapsed or Refractory Acute Leukemia, High-Risk Myelodysplasia, or Aggressive Myeloproliferative Disorders | November 28, 2007 | March 7, 2025 |
| NCT01885689 | Active, not recruiting | Phase 2 | Clofarabine and Melphalan Before Donor Stem Cell Transplant in Treating Patients With Myelodysplasia, Acute Leukemia in Remission, or Chronic Myelomonocytic Leukemia | February 10, 2014 | December 30, 2024 |
| NCT03912064 | Active, not recruiting | Phase 1 | A Phase 1 Trial of CD25/Treg-depleted DLI Plus Ipilimumab for Myeloid Disease Relapse After Matched-HCT | July 10, 2019 | July 1, 2024 |
| NCT03862157 | Active, not recruiting | Phase 1/Phase 2 | Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia | February 27, 2019 | January 31, 2025 |
| NCT03333486 | Active, not recruiting | Phase 2 | Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer | December 7, 2017 | August 28, 2024 |
| NCT00096122 | Completed | Phase 1/Phase 2 | Idarubicin, Cytarabine, and Tipifarnib in Treating Patients With Newly Diagnosed Myelodysplastic Syndromes or Acute Myeloid Leukemia | September 2004 | February 2010 |
| NCT00098423 | Completed | Phase 1 | Tanespimycin and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, Chronic Myelomonocytic Leukemia, or Myelodysplastic Syndromes | November 2004 | |
| NCT00101179 | Completed | Phase 1 | MS-275 and Azacitidine in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia | November 3, 2004 | February 3, 2014 |
| NCT00112593 | Completed | N/A | Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer | November 1999 | |
| NCT00002798 | Completed | Phase 3 | Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myelogenous Leukemia or Myelodysplastic Syndrome | August 1996 | |
| NCT00136409 | Completed | Phase 2 | A Study of Gleevec in Patients With Idiopathic Myelofibrosis or Chronic Myelomonocytic Leukemia (CMML) | May 2002 | December 2008 |
| NCT00171912 | Completed | Phase 2 | Imatinib Mesylate in Patients With Various Types of Malignancies Involving Activated Tyrosine Kinase Enzymes | September 2004 | January 2012 |
| NCT00283114 | Completed | Phase 1 | A Safety Study of Lintuzumab in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome | November 2005 | January 2010 |
| NCT00299156 | Completed | Phase 2 | Oral Clofarabine Study in Patients With Myelodysplastic Syndrome | March 2006 | December 2012 |
| NCT00313586 | Completed | Phase 2 | Azacitidine With or Without Entinostat in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia | August 2006 | July 2013 |
| NCT00351975 | Completed | Phase 1 | Belinostat and Azacitidine in Treating Patients With Advanced Hematologic Cancers or Other Diseases | June 2006 | March 2013 |
| NCT00357305 | Completed | Phase 1 | Vorinostat, Cytarabine, and Etoposide in Treating Patients With Relapsed and/or Refractory Acute Leukemia or Myelodysplastic Syndromes or Myeloproliferative Disorders | May 2006 | |
| NCT00357708 | Completed | Phase 1 | Vorinostat and Decitabine in Treating Patients With Relapsed, Refractory, or Poor-Prognosis Hematologic Cancer or Other Diseases | June 2006 | |
| NCT00381550 | Completed | Phase 2 | 3-AP and Fludarabine in Treating Patients With Myeloproliferative Disorders, Chronic Myelomonocytic Leukemia, or Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia | August 2006 | March 2011 |
| NCT00397813 | Completed | Phase 2 | Fludarabine Phosphate and Total Body Irradiation Followed by a Donor Peripheral Stem Cell Transplant in Treating Patients With Myelodysplastic Syndromes or Myeloproliferative Disorders | January 2006 | March 2018 |
| NCT00408681 | Completed | N/A | Lithium Carbonate in Treating Patients With Acute Intestinal Graft-Versus-Host-Disease (GVHD) After Donor Stem Cell Transplant | June 2006 | May 1, 2015 |
| NCT00451048 | Completed | Phase 2 | Sunitinib in Treating Patients With Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia | February 2007 | October 2012 |
| NCT00462605 | Completed | Phase 2 | MS-275 and GM-CSF in Treating Patients With Myelodysplastic Syndrome and/or Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphocytic Leukemia | April 2007 | March 2011 |
| NCT00489203 | Completed | Phase 2 | Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer | April 2007 | |
| NCT00719836 | Completed | Phase 1/Phase 2 | A Phase 1/2 Study of SB1518 for the Treatment of Advanced Myeloid Malignancies | August 2008 | January 2012 |
| NCT00795769 | Completed | Phase 2 | Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant | August 8, 2008 | June 10, 2009 |
| NCT00799461 | Completed | Phase 3 | Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late Complications | August 2008 | |
| NCT00809250 | Completed | Phase 1 | Vaccination With GM-K562 Cells in Patients With Advanced Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) After Allogeneic Hematopoetic Stem Cell Transplantation | November 2008 | January 2020 |
| NCT00856388 | Completed | N/A | Fludarabine Phosphate, Melphalan, Total-Body Irradiation, Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Bone Marrow Failure Disorders | January 14, 2009 | March 13, 2019 |
| NCT00860574 | Completed | Phase 2 | Treosulfan, Fludarabine Phosphate, and Total-Body Irradiation Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia | February 2009 | |
| NCT00890747 | Completed | Phase 1 | Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy | August 2009 | |
| NCT00946647 | Completed | Phase 1/Phase 2 | A Phase Ib/IIb, Open-label, Multi-center, Study of Oral Panobinostat Administered With 5-Azacitidine (in Adult Patients With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML). | December 2, 2009 | April 29, 2019 |
| NCT00988715 | Completed | Phase 1 | Donor Peripheral Blood Stem Cell Transplant and Pretargeted Radioimmunotherapy in Treating Patients With High-Risk Advanced Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome | April 21, 2010 | |
| NCT01048034 | Completed | Phase 2 | Evaluation of Azacitidine in Transfusion Dependent Patients With Low-risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) | January 2010 | August 2012 |
| NCT01053494 | Completed | N/A | Massage Therapy Given by Caregiver in Treating Quality of Life of Young Patients Undergoing Treatment for Cancer | April 2010 | February 2012 |
| NCT01083706 | Completed | Phase 2 | Azacitidine in Treating Patients With Relapsed Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia Who Have Undergone Stem Cell Transplant | April 2010 | |
| NCT01093586 | Completed | Phase 2 | Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies | September 2007 | December 2015 |
| NCT01098084 | Completed | Phase 2 | Decitabine in Patients With Chronic Myelomonocytic Leukemia (CMML) | November 2008 | June 2009 |
| NCT01101880 | Completed | Phase 2 | Clofarabine, Cytarabine, and Filgrastim in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia, Advanced Myelodysplastic Syndrome, and/or Advanced Myeloproliferative Neoplasm | August 2010 | July 2017 |
| NCT01146210 | Completed | Identification of de Novo Fanconi Anemia in Younger Patients With Newly Diagnosed Acute Myeloid Leukemia | May 2009 | May 2016 | |
| NCT01165996 | Completed | Phase 1/Phase 2 | Differentiation Therapy With Decitabine in Treating Patients With Myelodysplastic Syndrome | July 2010 | August 2012 |
| NCT01169012 | Completed | Phase 1 | PK Study of Oral and IV Clofarabine in High Risk Myelodysplasia+Acute Leukemias | September 2010 | January 2013 |
| NCT01199562 | Completed | Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant | December 2010 | December 2013 | |
| NCT01231919 | Completed | Phase 1 | MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia | January 2011 | |
| NCT01233921 | Completed | N/A | Palifermin in Preventing Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer | September 2010 | |
| NCT01241500 | Completed | Phase 3 | Randomized Study of ON 01910.Na in Refractory Myelodysplastic Syndrome Patients With Excess Blasts | November 2010 | October 3, 2018 |
| NCT01251627 | Completed | Phase 2 | Multicenter Study to Assess the Efficacy of Decitabine in the Treatment of Chronic Myelomonocytic Leukemia | April 2010 | June 2018 |
| NCT01300572 | Completed | Phase 1 | Yttrium-90 Anti-CD45 Monoclonal Antibody BC8 Followed by Donor Stem Cell Transplant in Treating Patients With High-Risk AML, ALL, or MDS | January 2012 | November 22, 2019 |
| NCT01305200 | Completed | Phase 3 | Supersaturated Calcium Phosphate Rinse in Preventing Oral Mucositis in Young Patients Undergoing Autologous or Donor Stem Cell Transplant | March 2011 | June 30, 2015 |
| NCT01338987 | Completed | Phase 2 | Pilot Study of Leuprolide to Improve Immune Function After Allogeneic Bone Marrow Transplantation | April 19, 2011 | November 19, 2020 |
| NCT01350947 | Completed | Phase 2 | A Study of 5-Azacitidine (Vidaza®) in Patients With Chronic Myelomonocytic Leukemia | April 2011 | September 2014 |
| NCT01384513 | Completed | Phase 2 | A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies | August 4, 2011 | November 16, 2022 |
| NCT01398462 | Completed | Phase 1 | Phase I Clinical Study of CWP232291 in Acute Myeloid Leukemia Patients | July 2011 | December 2015 |
| NCT01404741 | Completed | Phase 2 | 5-azacytidine Treatment Versus 5-azacytidine Followed by Allogeneic Stem Cell Transplantation in Elderly Patients With Myelodysplastic Syndrome (MDS) | July 2011 | July 2021 |
| NCT01427881 | Completed | Phase 2 | Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies | September 2011 | July 2015 |
| NCT01484015 | Completed | Phase 1 | Prolonged or Standard Infusion of Cefepime Hydrochloride in Treating Patients With Febrile Neutropenia | February 2011 | October 2012 |
| NCT01529827 | Completed | Phase 2 | Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies | February 28, 2012 | August 29, 2019 |
| NCT01588015 | Completed | Phase 1 | Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant | October 29, 2012 | February 2, 2024 |
| NCT01595295 | Completed | Registry on Hypomethylating Agents in Myeloid Neoplasms | February 9, 2009 | December 31, 2021 | |
| NCT01629082 | Completed | Phase 1 | Clofarabine Followed By Lenalidomide for High-Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia | June 6, 2012 | June 27, 2018 |
| NCT01664897 | Completed | Phase 2 | Erlotinib Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | May 16, 2013 | October 25, 2018 |
| NCT01736683 | Completed | Phase 2 | Study of Sotatercept for the Treatment of Anemia in low-or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) or Non-proliferative Chronic Myelomonocytic Leukemia (CMML) | November 28, 2012 | April 30, 2018 |
| NCT00118352 | Completed | Phase 2 | Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer | March 2005 | May 26, 2015 |
| NCT00005845 | Completed | Phase 1 | Tipifarnib in Treating Patients With Myelodysplastic Syndromes | June 2002 | |
| NCT00005942 | Completed | Phase 1/Phase 2 | Liposomal Daunorubicin and SU5416 in Treating Patients With Hematologic Cancer That Has Not Responded to Initial Therapy | March 2000 | |
| NCT00006251 | Completed | Phase 1/Phase 2 | Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic Cancer | May 2000 | |
| NCT00008177 | Completed | Phase 1 | Radiolabeled Monoclonal Antibody Therapy, Fludarabine Phosphate, and Low-Dose Total-Body Irradiation Followed by Donor Stem Cell Transplant and Immunosuppression Therapy in Treating Older Patients With Advanced Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes | July 27, 1999 | December 15, 2010 |
| NCT00012376 | Completed | Phase 1 | Chemotherapy Plus Sargramostim in Treating Patients With Refractory Myeloid Cancer | March 2001 | |
| NCT00014235 | Completed | N/A | Fludarabine Phosphate and Total-Body Radiation Followed by Donor Peripheral Blood Stem Cell Transplant and Immunosuppression in Treating Patients With Hematologic Malignancies | December 2000 | |
| NCT00015990 | Completed | Phase 2 | Thalidomide in Treating Patients With Myelodysplastic Syndrome | April 2001 | |
| NCT00025415 | Completed | Phase 1 | Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction | August 2001 | |
| NCT00027820 | Completed | Phase 1/Phase 2 | Total-Body Irradiation and Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer | August 2001 | September 5, 2004 |
| NCT00038051 | Completed | Phase 1 | Evaluation of the Anti-CD-33 Immunotoxin Hum-195/rGel in Patients With Advanced Myeloid Malignancies | May 1999 | February 2013 |
| NCT00038675 | Completed | N/A | Therapy of HES, PV, Atypical Chronic Myelocytic Leukemia (CML) or Chronic Myelomonocytic Leukemia (CMML), and Mastocytosis With Imatinib Mesylate | June 2001 | November 2013 |
| NCT00039416 | Completed | Phase 2 | Imatinib Mesylate in Treating Patients With Myelofibrosis | April 2002 | |
| NCT00052520 | Completed | Phase 1/Phase 2 | Biological Therapy in Treating Patients With Advanced Myelodysplastic Syndrome, Acute or Chronic Myeloid Leukemia, or Acute Lymphoblastic Leukemia Who Are Undergoing Stem Cell Transplantation | September 2002 | June 2013 |
| NCT00067808 | Completed | Phase 2 | Study of Three Different Schedules of Low-Dose Decitabine in Myelodysplastic Syndrome (MDS) | October 2003 | May 2009 |
| NCT00078858 | Completed | Phase 1/Phase 2 | Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant | September 2003 | |
| NCT00079313 | Completed | Phase 2 | Imatinib (Gleevec(Registered Trademark)) to Treat Chronic Myelomonocytic Leukemia and Atypical Chronic Myelogenous Leukemia | January 14, 2004 | October 25, 2010 |
| NCT00084916 | Completed | Phase 2 | CCI-779 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, or Chronic Myelogenous Leukemia in Blastic Phase | April 2004 | |
| NCT00087204 | Completed | Phase 1 | Rebeccamycin Analog in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia, or Chronic Myelogenous Leukemia | May 2004 | |
| NCT00095797 | Completed | Phase 1 | XK469R in Treating Patients With Refractory Hematologic Cancer | October 2004 | |
| NCT01757639 | Completed | Phase 1 | Ipilimumab in Treating Patients With Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia | December 14, 2012 | |
| NCT01760655 | Completed | Phase 2 | Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies | December 24, 2012 | December 5, 2022 |
| NCT01772420 | Completed | Phase 2 | Phase II Study of Lenalidomide and Eltrombopag in Patients With Symptomatic Anemia | October 2012 | July 9, 2020 |
| NCT01789255 | Completed | Phase 2 | Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies | June 2013 | March 2014 |
| NCT01812252 | Completed | Phase 2 | Chemotherapy in Treating Patients With Myelodysplastic Syndrome Before Donor Stem Cell Transplant | August 19, 2013 | October 26, 2022 |
| NCT01823198 | Completed | Phase 1/Phase 2 | Donor Natural Killer Cells and Donor Stem Cell Transplant in Treating Patients With High Risk Myeloid Malignancies | June 11, 2013 | May 10, 2022 |
| NCT01831232 | Completed | N/A | Idarubicin, Cytarabine, and Pravastatin Sodium in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes | May 2013 | January 2016 |
| NCT01834248 | Completed | Phase 1 | DEC-205/NY-ESO-1 Fusion Protein CDX-1401and Decitabine in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia | July 30, 2013 | March 21, 2016 |
| NCT01872819 | Completed | N/A | Treatment for Relapsed/Refractory AML Based on a High Throughput Drug Sensitivity Assay | August 2, 2013 | November 17, 2014 |
| NCT01926587 | Completed | Phase 1/Phase 2 | Phase II Part 2 Expansion of Oral Rigosertib in Combination With Azacitidine | August 2013 | February 16, 2021 |
| NCT01928537 | Completed | Phase 3 | Efficacy and Safety of IV Rigosertib in MDS Patients With Excess Blasts Progressing After Azacitidine or Decitabine | August 2013 | June 29, 2017 |
| NCT02129101 | Completed | Phase 1 | Azacitidine and Sonidegib or Decitabine in Treating Patients With Myeloid Malignancies | May 2014 | October 25, 2019 |
| NCT02190695 | Completed | Phase 2 | Leukemia SPORE Phase II DAC Study for R/R and Elderly Acute AML and MDS | April 1, 2013 | April 16, 2020 |
| NCT02210858 | Completed | Phase 1/Phase 2 | Tipifarnib in Treating Patients With Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or Undifferentiated Myeloproliferative Disorders | May 2000 | March 2017 |
| NCT02268253 | Completed | Phase 2 | Tagraxofusp (SL-401) in Patients With CMML or MF | December 2014 | March 7, 2023 |
| NCT02367456 | Completed | Phase 1 | A Combination Study of PF-04449913 (Glasdegib) and Azacitidine In Untreated MDS, AML and CMML Patients | April 28, 2015 | March 7, 2022 |
| NCT02397720 | Completed | Phase 2 | Nivolumab and Azacitidine With or Without Ipilimumab in Treating Patients With Refractory/Relapsed or Newly Diagnosed Acute Myeloid Leukemia | April 7, 2015 | October 9, 2023 |
| NCT02553941 | Completed | Phase 1 | Ibrutinib and Azacitidine for Treatment of Higher Risk Myelodysplastic Syndrome | May 17, 2016 | November 7, 2019 |
| NCT02556931 | Completed | Phase 2 | Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft Malignancies | December 2015 | April 2021 |
| NCT02649764 | Completed | Phase 1 | Prexasertib (LY2606368), Cytarabine, and Fludarabine in Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome | May 4, 2016 | July 12, 2022 |
| NCT02666950 | Completed | Phase 2 | WEE1 Inhibitor AZD1775 With or Without Cytarabine in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome | May 5, 2017 | October 17, 2018 |
| NCT02960646 | Completed | Phase 1 | Engineered Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies | January 18, 2017 | February 13, 2023 |
| NCT03018223 | Completed | Phase 1 | Calcineurin Inhibitor-Free GVHD Prevention Regimen After Related Haplo PBSCT | January 31, 2017 | March 18, 2021 |
| NCT03047993 | Completed | Phase 1/Phase 2 | Glutaminase Inhibitor CB-839 and Azacitidine in Treating Patients With Advanced Myelodysplastic Syndrome | November 15, 2017 | March 16, 2023 |
| NCT03066648 | Completed | Phase 1 | Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With AML or High Risk MDS | July 6, 2017 | September 8, 2023 |
| NCT03072043 | Completed | Phase 1/Phase 2 | Phase 1b/2 Safety and Efficacy of APR-246 w/Azacitidine for tx of TP53 Mutant Myeloid Neoplasms | May 18, 2017 | December 8, 2021 |
| NCT03096782 | Completed | Phase 2 | Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or Lymphoma | October 13, 2017 | September 20, 2022 |
| NCT03263637 | Completed | Phase 1 | Study to Assess Safety, Tolerability, Pharmacokinetics and Antitumor Activity of AZD4573 in Relapsed/Refractory Haematological Malignancies | October 24, 2017 | September 30, 2021 |
| NCT03306264 | Completed | Phase 3 | Study of ASTX727 vs IV Decitabine in MDS, CMML, and AML | February 15, 2018 | March 28, 2023 |
| NCT03358719 | Completed | Phase 1 | DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, Decitabine, and Nivolumab in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia | March 27, 2018 | August 25, 2021 |
| NCT03363399 | Completed | Flow Cytometric Analysis of Peripheral Blood Neutrophil Myeloperoxidase Expression and Myelodysplastic Syndromes | February 22, 2018 | September 6, 2018 | |
| NCT03493646 | Completed | Phase 2 | Evaluating in Vivo AZA Incorporation in Mononuclear Cells Following Vidaza or CC486 | May 18, 2018 | September 21, 2021 |
| NCT03515512 | Completed | Phase 1 | IDH2 Inhibition Using Enasidenib as Maintenance Therapy for IDH2-mutant Myeloid Neoplasms Following Allogeneic Stem Cell Transplantation | July 17, 2018 | February 13, 2023 |
| NCT03526666 | Completed | Ascorbic Acid Levels in MDS, AML, and CMML Patients | November 1, 2017 | October 31, 2018 | |
| NCT03734601 | Completed | Phase 2 | Total Body Irradiation +/- Total Lymphoid Irradiation & Anti-Thymocyte Globulin in Non-myeloablative Hematopoietic Cell Transplantation | November 5, 2018 | November 17, 2020 |
| NCT03746041 | Completed | Phase 1 | A Phase I Pilot Study of Abaloparatide + Bevacizumab in Myelodysplastic Syndromes | February 14, 2019 | June 6, 2022 |
| NCT03813186 | Completed | Phase 1 | Effect of Food on Blood Levels of ASTX727 | November 8, 2018 | December 16, 2019 |
| NCT04146038 | Completed | Phase 2 | Salsalate, Venetoclax, and Decitabine or Azacitidine for the Treatment of Acute Myeloid Leukemia or Advanced Myelodysplasia/Myeloproliferative Disease | October 26, 2020 | October 25, 2022 |
| NCT04842604 | Completed | Phase 3 | Continuation Study of B1371019(NCT03416179) and B1371012(NCT02367456) Evaluating Azacitidine With Or Without Glasdegib In Patients With Previously Untreated AML, MDS or CMML | May 17, 2021 | December 2, 2022 |
| NCT05209152 | Completed | Phase 1 | AMG 176 With Azacitidine in Subjects With Myelodysplastic Syndrome /Chronic Myelomonocytic Leukemia | November 14, 2022 | December 19, 2023 |
| NCT04093570 | Enrolling by invitation | Phase 2 | A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose), With a Food Effect Substudy at Select Study Centers | September 30, 2019 | December 31, 2024 |
| NCT06355583 | Not yet recruiting | Phase 2 | Intestinal Microbiota Transplant Prior to Allogeneic Stem Cell Transplant (MAST) Trial | April 15, 2024 | May 1, 2027 |
| NCT06439199 | Not yet recruiting | Biological, Prospective Study Evaluating the Dosage of Plasma Cytokines Including the FLT3 Ligand and IL6 of Patients Treated With Non-intensive Chemotherapy | June 15, 2024 | December 15, 2026 | |
| NCT05739409 | Not yet recruiting | N/A | LILRB4 STAR-T Cell Therapy for Monocytic Leukemia | February 2023 | August 2024 |
| NCT04953312 | Not yet recruiting | N/A | Calprotectin, a Biomarker of COVID-19 Severity (CALPRO) | January 2023 | July 2024 |
| NCT06111612 | Not yet recruiting | Intensive Conditioning With Thiotepa Combined With Bu/Flu/Ara-C in Allo-HSCT for Myeloid Malignancies With Extramedullary Involvement | January 1, 2024 | January 1, 2027 | |
| NCT06159491 | Not yet recruiting | Phase 1/Phase 2 | Pacritinib in CMML | January 2, 2024 | May 2027 |
| NCT06071624 | Recruiting | Phase 1 | Chimeric Antigen Receptor T Cell Therapy Redirected to CD4 (CD4CAR)as a Second Line Treatment for Chronic Myelomonocytic Leukemia, CMML. | February 21, 2024 | December 2043 |
| NCT05031897 | Recruiting | Phase 2 | Reduced-Intensity Conditioning for the Prevention of Treatment-Related Mortality in Patients Who Undergo a Hematopoietic Stem Cell Transplant | October 25, 2021 | October 1, 2024 |
| NCT05038592 | Recruiting | Phase 1/Phase 2 | Tagraxofusp and Decitabine for the Treatment of Chronic Myelomonocytic Leukemia | March 4, 2022 | January 29, 2025 |
| NCT05600894 | Recruiting | Phase 2 | Venetoclax in Combination With ASTX727 for the Treatment of Chronic Myelomonocytic Leukemia and Other Myelodysplastic Syndrome/Myeloproliferative Neoplasm | June 27, 2023 | August 31, 2025 |
| NCT05428969 | Recruiting | Phase 1/Phase 2 | A Study to Assess Safety, Tolerability and Preliminary Efficacy of Bexmarilimab in Combination With Standard of Care in Patients With Hematological Malignancies (BEXMAB) | June 2, 2022 | December 31, 2024 |
| NCT03672539 | Recruiting | Phase 2 | Liposome-encapsulated Daunorubicin-Cytarabine and Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome | November 7, 2018 | November 30, 2025 |
| NCT03683433 | Recruiting | Phase 2 | Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation | September 18, 2018 | September 20, 2025 |
| NCT05364762 | Recruiting | Phase 2 | Adding Itacitinib to Cyclophosphamide and Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Hematopoietic Stem Cell Transplants | November 23, 2022 | April 28, 2024 |
| NCT03418038 | Recruiting | Phase 2 | Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia | March 23, 2018 | March 2026 |
| NCT05233618 | Recruiting | Phase 1 | Study of Tagraxofusp for Post-Transplant Maintenance for Patients With CD 123+ AML, MF and CMML (HSCT 002) | July 13, 2022 | October 1, 2026 |
| NCT06001385 | Recruiting | Phase 2 | HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxis | December 8, 2023 | June 30, 2026 |
| NCT04802161 | Recruiting | Phase 2 | Comparing the Addition of an Anti-Cancer Drug, Pomalidomide, to the Usual Chemotherapy Treatment (Daunorubicin and Cytarabine Liposome) in Newly Diagnosed Acute Myeloid Leukemia With Myelodysplastic Syndrome-Related Changes | August 24, 2022 | December 31, 2024 |
| NCT04888741 | Recruiting | Phase 2 | Methods of T Cell Depletion Trial (MoTD) | February 22, 2021 | January 2026 |
| NCT04937166 | Recruiting | Phase 1 | A Study of Dual-SIgnaling Protein 107 (DSP107) for Patients With Hematological Malignancies | January 13, 2022 | December 2024 |
| NCT04980404 | Recruiting | Phase 1 | Inqovi Maintenance Therapy in Myeloid Neoplasms | September 17, 2021 | August 2024 |
| NCT04708054 | Recruiting | Phase 2 | Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS | October 21, 2021 | December 31, 2024 |
| NCT04730258 | Recruiting | Phase 1/Phase 2 | A Study of CFI-400945 With or Without Azacitidine in Patients With AML, MDS or CMML | April 16, 2021 | January 2026 |
| NCT05970822 | Recruiting | Phase 1 | Study of BC3402 in Combination With Azacitidine in Patients With MDS and CMML | June 18, 2023 | December 2025 |
| NCT05641259 | Recruiting | Phase 1 | A Study to Assess Safety and Preliminary Efficacy of LP-108 Combined With Azacitidine In Subjects With AML, MDS, CMML | February 14, 2023 | December 31, 2025 |
| NCT03964506 | Recruiting | Early Phase 1 | Hyperbaric Oxygen Therapy and Allogeneic Peripheral Blood Stem Cell (PBSC) Transplant | July 1, 2020 | March 1, 2025 |
| NCT03999723 | Recruiting | Phase 2 | Combining Active and Passive DNA Hypomethylation | September 11, 2019 | December 2027 |
| NCT06218628 | Recruiting | Phase 1 | Pacritinib w/ Talazoparib in Pts w/ Myeloproliferative Neoplasms Unresponsive to JAK2 Inhibition | April 5, 2024 | August 27, 2030 |
| NCT04160052 | Recruiting | Phase 1/Phase 2 | Venetoclax and Azacitidine for the Treatment of High-Risk Recurrent or Refractory Myelodysplastic Syndrome | October 1, 2019 | December 31, 2025 |
| NCT04167917 | Recruiting | Phase 1 | NTX-301 in MDS/AML | January 6, 2021 | March 31, 2028 |
| NCT04195633 | Recruiting | Phase 2 | Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies | January 25, 2021 | December 31, 2026 |
| NCT04239157 | Recruiting | Phase 2 | A Phase II, Open-Label, Study of Subcutaneous Canakinumab, an Anti-IL-1β Human Monoclonal Antibody, for Patients With Low or Int-1 Risk IPSS/IPSS-R Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia | August 25, 2020 | December 31, 2026 |
| NCT04358393 | Recruiting | Phase 1/Phase 2 | A Study of APG-115 Alone or Combined With Azacitidine in Patients With AML, CMML, or MDS | December 4, 2020 | December 30, 2025 |
| NCT05807932 | Recruiting | Phase 1/Phase 2 | Venetoclax in Addition to Sequential Conditioning With Fludarabine / Amsacrine / Ara-C (FLAMSA) + Treosulfan for Allogeneic Blood Stem Cell Transplantation in Patients With MDS, CMML or sAML | June 26, 2023 | January 30, 2028 |
| NCT04493138 | Recruiting | Phase 1/Phase 2 | Azacitidine and Quizartinib for the Treatment of Myelodysplastic Syndrome or Myelodysplastic/Myeloproliferative Neoplasm With FLT3 or CBL Mutations | July 21, 2020 | December 31, 2025 |
| NCT02727803 | Recruiting | Phase 2 | Personalized NK Cell Therapy in CBT | May 19, 2016 | May 31, 2025 |
| NCT03383575 | Recruiting | Phase 2 | Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome | January 17, 2018 | February 28, 2025 |
| NCT04581512 | Recruiting | Phase 1/Phase 2 | Study to Evaluate the Safety and Tolerability of EP0042 | November 2, 2020 | December 2025 |
| NCT05636514 | Recruiting | Phase 1 | Combined Evaluation of Epigenetic and Sensitising Therapy in AML and MDS | December 14, 2022 | December 5, 2025 |
| NCT04655755 | Recruiting | Phase 1/Phase 2 | Venetoclax in Combination With ASTX727 for the Treatment of Treatment-Naive High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia | January 19, 2021 | July 20, 2026 |
| NCT03326921 | Suspended | Phase 1 | HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant | February 23, 2018 | July 16, 2028 |
| NCT03128034 | Suspended | Phase 1/Phase 2 | 211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia | October 24, 2017 | March 31, 2027 |
| NCT03670966 | Suspended | Phase 1/Phase 2 | 211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome | July 10, 2019 | March 20, 2027 |
| NCT00387426 | Terminated | Phase 2 | Sunitinib in Treating Patients With Idiopathic Myelofibrosis | September 2006 | February 2009 |
| NCT01010256 | Terminated | The Expression of PTEN Protein and mRNA in Malignant Cells of Chronic Myelomonocytic Leukemia | November 1, 2009 | October 3, 2019 | |
| NCT00852709 | Terminated | Phase 1 | Phase I Dose-Escalation Trial of Clofarabine Followed by Escalating Doses of Fractionated Cyclophosphamide in Children With Relapsed or Refractory Acute Leukemias | September 1, 2007 | November 20, 2009 |
| NCT00708721 | Terminated | Phase 1/Phase 2 | Low-dose Oral Clofarabine for the Treatment of IPSS INT-1, INT-2 or HIGH Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia | March 2008 | November 2014 |
| NCT00589316 | Terminated | Phase 1 | Iodine I 131 Monoclonal Antibody BC8, Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation and Donor Bone Marrow Transplant in Treating Patients With Advanced Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or High-Risk Myelodysplastic Syndrome | October 5, 2007 | October 1, 2021 |
| NCT01749111 | Terminated | Phase 3 | Comparison Between Cyclophosphamide and Combination of Methotrexate + Calcineurin Inhibitor for GVHD Prophylaxis | December 2012 | August 2016 |
| NCT00509249 | Terminated | Phase 2 | Aflibercept in Treating Patients With Myelodysplastic Syndromes | September 2007 | December 2010 |
| NCT01773395 | Terminated | Phase 2 | GVAX vs. Placebo for MDS/AML After Allo HSCT | January 8, 2013 | November 24, 2021 |
| NCT00119366 | Terminated | Phase 2 | Iodine I 131 Monoclonal Antibody BC8, Fludarabine Phosphate, Total Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome | May 2003 | May 8, 2019 |
| NCT00113321 | Terminated | Phase 2 | Low-Dose Decitabine in Myelodysplastic Syndrome Post Azacytidine Failure | March 2005 | November 2008 |
| NCT01620216 | Terminated | Phase 2 | Targeted Therapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia | May 11, 2012 | April 30, 2017 |
| NCT01908387 | Terminated | Phase 1 | Phase 1 Study of CC-486 in Japanese Subjects With Hematological Neoplasms | July 2013 | July 2015 |
| NCT00074750 | Terminated | Phase 1 | Study of DT388GMCSF Fusion Protein in Acute Myelogenous Leukemia (AML) and Chronic Myelomonocytic Leukemia (CMML) | December 2003 | December 2004 |
| NCT05107856 | Terminated | Phase 1 | PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or B-cell Malignancies | March 22, 2022 | January 19, 2024 |
| NCT01159067 | Terminated | Phase 2 | Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron Overload | July 2010 | August 9, 2011 |
| NCT03146871 | Terminated | Phase 2 | Recombinant EphB4-HSA Fusion Protein and Azacitidine or Decitabine for Relapsed or Refractory Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia Patients Previously Treated With a Hypomethylating Agent | April 20, 2017 | March 27, 2019 |
| NCT01368757 | Unknown status | Phase 1/Phase 2 | Lenalidomide in Patients With Chronic Myelomonocytic Leukemia | June 2010 | May 2015 |
| NCT03588078 | Unknown status | Phase 1/Phase 2 | Study of the Safety and Efficacy of APR-246 in Combination With Azacitidine | September 15, 2018 | May 15, 2021 |
| NCT00885508 | Unknown status | Phase 2 | A Study of the Efficacy and Safety of Lenalidomide Combined to Escalating Doses of Chemotherapy in Intermediate-2-or High Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) With Del 5q | February 2009 | December 2015 |
| NCT03280888 | Unknown status | Relevance of Peripheral Cells in the Pathophysiology of Chronic Myelomonocytic Leukemia (CMML) | November 5, 2014 | November 5, 2018 | |
| NCT01133886 | Unknown status | Phase 2 | Use of Decitabine in Myelodysplastic Syndrome (MDS) Following Azacitidine (AZA) Failure | September 2010 | September 2013 |
| NCT01894477 | Unknown status | Phase 2 | Treo/Flu/TBI With Donor Stem Cell Transplant for Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia | November 2013 | June 2022 |
| NCT01558778 | Withdrawn | N/A | Mechanical Stimulation in Preventing Bone Density Loss in Patients Undergoing Donor Stem Cell Transplant | May 2012 | |
| NCT02564536 | Withdrawn | Phase 1 | Pacritinib in Combination With Low Dose Decitabine in Intermediate-High Risk Myelofibrosis or Myeloproliferative Neoplasm (MPN)/Myelodysplastic Syndrome (MDS) | June 2017 | June 30, 2020 |
| NCT05246384 | Withdrawn | Phase 1/Phase 2 | Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RP7214 in Combination With Azacitidine in Patients With Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia and Acute Myeloid Leukemia | January 2023 | November 2025 |
| NCT06085638 | Withdrawn | Phase 1/Phase 2 | Phase I/II Study of SY-1425 (Tamibarotene) in Combination With Azacitidine and Venetoclax for Patients With Chronic Myelomonocytic Leukemia | September 14, 2023 | October 20, 2023 |
| NCT03602898 | Withdrawn | Phase 2 | Comparing ATG or Post-Transplant Cyclophosphamide to Calcineurin Inhibitor-Methotrexate as GVHD Prophylaxis After Myeloablative Unrelated Donor Peripheral Blood Stem Cell Transplantation | June 1, 2021 | September 17, 2023 |
| NCT05456269 | Withdrawn | Phase 1 | A Study of Bisantrene Combined With Cytarabine or With Decitabine for Adult Subjects With Extramedullary AML and MDS | July 29, 2022 | August 31, 2023 |
| NCT05895201 | Withdrawn | Phase 1/Phase 2 | High-Dose Post-Transplant Cyclophosphamide, Bortezomib, and Sitagliptin for the Prevention of GVHD | November 2023 | December 2025 |
- Disase is a (Disease Ontology)
- DOID:1036
- Cross Reference ID (Disease Ontology)
- GARD:8225
- Cross Reference ID (Disease Ontology)
- ICDO:9945/3
- Cross Reference ID (Disease Ontology)
- NCI:C3178
- HPO Human Phenotype ID (Human Phenotype Ontology)
- HP:0012325